Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2017 · 10-Q
Revenue$1.34M$1.34M+968.8% vs Q3 2016 Net Income-$20.71M-$20.71MN/M vs Q3 2016 EPS Diluted-$0.67-$0.67N/M vs Q3 2016 Operating Income-$21,309,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,586,000N/M Margins · derivedOperating margin-1595.0%+13339.4 pt vs Q3 2016
Net margin-1549.9%+12973.3 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 8, 2017 · 39 d after period end